Long-term safety study of an investigational migraine medication
Part of Brain & nervous system clinical trials.
This study is testing the long-term safety of an investigational migraine medication called elismetrep. It is for people who have already completed a previous study of this drug and are willing to continue using a smartphone app to track their symptoms daily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous study of this migraine medication.
- You must have used the daily electronic diary and reported your migraine symptoms during the previous study.
- You must be willing to use a smartphone app for daily symptom tracking.
- If you are a woman who could become pregnant, you must agree to use effective birth control during the study.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called elismetrep (K-304) for quickly stopping migraine pain and other symptoms. If you have regular migraines, this could offer a new option that works fast when a migraine starts.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
This trial tests a new medicine called IPN10200 to see if it can prevent episodic or chronic migraine. It is for adults who have had migraine for at least a year and have tried at least one preventive treatment before.
This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.
Hear when a new Acute Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.